Not all immune-checkpoint inhibitors are created equal: Meta-analysis and systematic review of immune-related adverse events in cancer trials

Critical Reviews in Oncology/Hematology

Volumn 119, Issue , 2017, Pages 1-12

  El Osta, B ^a,b   Hu, F ^c   Sadek, R ^c   Chintalapally, R ^c   Tang, S C ^c,d  

^a ATLANTA VA MEDICAL CENTER   (United States)

^b EMORY UNIVERSITY   (United States)

^c MEDICAL COLLEGE OF GEORGIA   (United States)

^d TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Checkpoint inhibitors; Clinical trials; Immune related adverse events; Meta analysis; Systematic review

Indexed keywords

ALANINE AMINOTRANSFERASE; ATEZOLIZUMAB; AVELUMAB; BILIRUBIN; CHECKPOINT KINASE INHIBITOR; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DURVALUMAB; IPILIMUMAB; NIVOLUMAB; PEMBROLIZUMAB; PIDILIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; TICILIMUMAB; TRIACYLGLYCEROL LIPASE; CD274 PROTEIN, HUMAN; CTLA4 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN;

ADVERSE EVENT; ALOPECIA; CANCER COMBINATION CHEMOTHERAPY; COLITIS; DIARRHEA; DRUG RESPONSE; DRUG TARGETING; HUMAN; HYPERGLYCEMIA; HYPERTHYROIDISM; HYPOPHYSITIS; HYPOTHYROIDISM; IMMUNE RELATED ADVERSE EVENT; IMMUNOCOMPETENT CELL; INCIDENCE; INFUSION RELATED REACTION; MALIGNANT NEOPLASM; MELANOMA; META ANALYSIS; PNEUMONIA; PRURITUS; RASH; REVIEW; SIDE EFFECT; SOLID MALIGNANT NEOPLASM; SYSTEMATIC REVIEW; TUMOR CELL; TUMOR IMMUNITY; VITILIGO; ANTAGONISTS AND INHIBITORS; IMMUNOLOGY; NEOPLASM;

ANTIBODIES, MONOCLONAL; B7-H1 ANTIGEN; CTLA-4 ANTIGEN; HUMANS; NEOPLASMS; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 85032727826     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2017.09.002     Document Type: Review

References (81)

1. Altomonte, M., Di Giacomo, A., Queirolo, P., Ascierto, P., Spagnolo, F., Bajetta, E., et al. Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme. J. Exp. Clin. Cancer Res., 32, 2013, 82, 10.1186/1756-9966-32-82.
2. Ansell, S.M., Hurvitz, S.A., Koenig, P.A., LaPlant, B.R., Kabat, B.F., Fernando, D., et al. Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma. Clin. Cancer Res. 15:20 (2009), 6446–6453, 10.1158/1078-0432.ccr-09-1339.
3. Ansell, S.M., Lesokhin, A.M., Borrello, I., Halwani, A., Scott, E.C., Gutierrez, M., et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N. Engl. J. Med. 372:4 (2015), 311–319, 10.1056/nejmoa1411087.
4. Antonia, S., Goldberg, S.B., Balmanoukian, A., Chaft, J.E., Sanborn, R.E., Gupta, A., et al. Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study. Lancet Oncol. 17:3 (2016), 299–308, 10.1016/s1470-2045(15)00544-6.
5. Armand, P., Nagler, A., Weller, E.A., Devine, S.M., Avigan, D.E., Chen, Y.B., et al. Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. J. Clin. Oncol. 31:33 (2013), 4199–4206, 10.1200/JCO.2012.48.3685.
6. Balar, A.V., Galsky, M.D., Rosenberg, J.E., Powles, T., Petrylak, D.P., Bellmunt, J., et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet 389:10064 (2017), 67–76, 10.1016/s0140-6736(16)32455-2.
7. Bashey, A., Medina, B., Corringham, S., Pasek, M., Carrier, E., Vrooman, L., et al. CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation. Blood 113:7 (2009), 1581–1588, 10.1182/blood-2008-07-168468.
8. Berger, R., Rotem-Yehudar, R., Slama, G., Landes, S., Kneller, A., Leiba, M., et al. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin. Cancer Res. 14:10 (2008), 3044–3051, 10.1158/1078-0432.ccr-07-4079.
9. Bertrand, A., Kostine, M., Barnetche, T., Truchetet, M.E., Schaeverbeke, T., Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med., 13, 2015, 211, 10.1186/s12916-015-0455-8.
10. Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D.R., Steins, M., Ready, N.E., et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med. 373:17 (2015), 1627–1639, 10.1056/NEJMoa1507643.
11. Brahmer, J.R., Drake, C.G., Wollner, I., Powderly, J.D., Picus, J., Sharfman, W.H., et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 28:19 (2010), 3167–3175, 10.1200/jco.2009.26.7609.
12. Brahmer, J.R., Tykodi, S.S., Chow, L.Q., Hwu, W.J., Topalian, S.L., Hwu, P., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366:26 (2012), 2455–2465, 10.1056/NEJMoa1200694.
13. Calabro, L., Morra, A., Fonsatti, E., Cutaia, O., Amato, G., Giannarelli, D., et al. Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial. Lancet Oncol. 14:11 (2013), 1104–1111, 10.1016/s1470-2045(13)70381-4.
14. Camacho, L.H., Antonia, S., Sosman, J., Kirkwood, J.M., Gajewski, T.F., Redman, B., et al. Phase I/II trial of tremelimumab in patients with metastatic melanoma. J. Clin. Oncol. 27:7 (2009), 1075–1081, 10.1200/jco.2008.19.2435.
15. Carthon, B.C., Wolchok, J.D., Yuan, J., Kamat, A., Ng Tang, D.S., Sun, J., et al. Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin. Cancer Res. 16:10 (2010), 2861–2871, 10.1158/1078-0432.ccr-10-0569.
16. Chen, T.W., Razak, A.R., Bedard, P.L., Siu, L.L., Hansen, A.R., A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors. Ann. Oncol. 26:9 (2015), 1824–1829, 10.1093/annonc/mdv182.
17. Chiarion Sileni, V., Pigozzo, J., Ascierto, P.A., Grimaldi, A.M., Maio, M., Di Guardo, L., et al. Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme. J. Exp. Clin. Cancer Res., 33, 2014, 30, 10.1186/1756-9966-33-30.
18. Chung, K.Y., Gore, I., Fong, L., Venook, A., Beck, S.B., Dorazio, P., et al. Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer. J. Clin. Oncol. 28:21 (2010), 3485–3490, 10.1200/jco.2010.28.3994.
19. Danielli, R., Ridolfi, R., Chiarion-Sileni, V., Queirolo, P., Testori, A., Plummer, R., et al. Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy. Cancer Immunol. Immunother. 61:1 (2012), 41–48, 10.1007/s00262-011-1089-0.
20. Davids, M.S., Kim, H.T., Bachireddy, P., Costello, C., Liguori, R., Savell, A., et al. Ipilimumab for patients with relapse after allogeneic transplantation. N. Engl. J. Med. 375:2 (2016), 143–153, 10.1056/nejmoa1601202.
21. Di Giacomo, A.M., Danielli, R., Calabro, L., Bertocci, E., Nannicini, C., Giannarelli, D., et al. Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy). Cancer Immunol. Immunother. 60:4 (2011), 467–477, 10.1007/s00262-010-0958-2.
22. Downey, S.G., Klapper, J.A., Smith, F.O., Yang, J.C., Sherry, R.M., Royal, R.E., et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin. Cancer Res. 13:22 Pt. 1 (2007), 6681–6688, 10.1158/1078-0432.ccr-07-0187.
23. Eggermont, A.M., Chiarion-Sileni, V., Grob, J.J., Dummer, R., Wolchok, J.D., Schmidt, H., et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 16:5 (2015), 522–530, 10.1016/s1470-2045(15)70122-1.
24. Eggermont, A.M., Chiarion-Sileni, V., Grob, J.J., Dummer, R., Wolchok, J.D., Schmidt, H., et al. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N. Engl. J. Med. 375:19 (2016), 1845–1855, 10.1056/nejmoa1611299.
25. Eigentler, T.K., Schlaak, M., Hassel, J.C., Loquai, C., Stoffels, I., Gutzmer, R., et al. Effectiveness and tolerability of ipilimumab: experiences from 198 patients included in a named-patient program in various daily-practice settings and multiple institutions. J. Immunother. 37:7 (2014), 374–381, 10.1097/cji.0000000000000046.
26. Fehrenbacher, L., Spira, A., Ballinger, M., Kowanetz, M., Vansteenkiste, J., Mazieres, J., et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet 387:10030 (2016), 1837–1846, 10.1016/s0140-6736(16)00587-0.
27. Ferris, R.L., Blumenschein, G. Jr., Fayette, J., Guigay, J., Colevas, A.D., Licitra, L., et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N. Engl. J. Med., 2016, 10.1056/NEJMoa1602252.
28. Floyd, M., El Osta, B., Tang, S.-C., First report of parkinsonism associated with Indoximod, an immune-modulating agent. J. Global Oncol., 2016, 10.1200/jgo.2016.007492.
29. Garon, E.B., Rizvi, N.A., Hui, R., Leighl, N., Balmanoukian, A.S., Eder, J.P., et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N. Engl. J. Med. 372:21 (2015), 2018–2028, 10.1056/NEJMoa1501824.
30. Gettinger, S.N., Horn, L., Gandhi, L., Spigel, D.R., Antonia, S.J., Rizvi, N.A., et al. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J. Clin. Oncol. 33:18 (2015), 2004–2012, 10.1200/JCO.2014.58.3708.
31. Hamid, O., Robert, C., Daud, A., Hodi, F.S., Hwu, W.J., Kefford, R., et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med. 369:2 (2013), 134–144, 10.1056/NEJMoa1305133.
32. Herbst, R.S., Baas, P., Kim, D.W., Felip, E., Perez-Gracia, J.L., Han, J.Y., et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387:10027 (2016), 1540–1550, 10.1016/s0140-6736(15)01281-7.
33. Hersh, E.M., O'Day, S.J., Powderly, J., Khan, K.D., Pavlick, A.C., Cranmer, L.D., et al. A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naive patients with advanced melanoma. Invest. New Drugs 29:3 (2011), 489–498, 10.1007/s10637-009-9376-8.
34. Hodi, F.S., O'Day, S.J., McDermott, D.F., Weber, R.W., Sosman, J.A., Haanen, J.B., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363:8 (2010), 711–723, 10.1056/nejmoa1003466.
35. Hodi, F.S., Lee, S., McDermott, D.F., Rao, U.N., Butterfield, L.H., Tarhini, A.A., et al. Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial. JAMA 312:17 (2014), 1744–1753, 10.1001/jama.2014.13943.
36. Kaufman, H.L., Russell, J., Hamid, O., Bhatia, S., Terheyden, P., D'Angelo, S.P., et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol. 17:10 (2016), 1374–1385, 10.1016/s1470-2045(16)30364-3.
37. Keir, M.E., Butte, M.J., Freeman, G.J., Sharpe, A.H., PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 26 (2008), 677–704, 10.1146/annurev.immunol.26.021607.090331.
38. Kirkwood, J.M., Tarhini, A.A., Panelli, M.C., Moschos, S.J., Zarour, H.M., Butterfield, L.H., et al. Next generation of immunotherapy for melanoma. J. Clin. Oncol. 26:20 (2008), 3445–3455, 10.1200/jco.2007.14.6423.
39. Kirkwood, J.M., Lorigan, P., Hersey, P., Hauschild, A., Robert, C., McDermott, D., et al. Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma. Clin. Cancer Res. 16:3 (2010), 1042–1048, 10.1158/1078-0432.ccr-09-2033.
40. Kwon, E.D., Drake, C.G., Scher, H.I., Fizazi, K., Bossi, A., van den Eertwegh, A.J., et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 15:7 (2014), 700–712, 10.1016/s1470-2045(14)70189-5.
41. Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J.J., Cowey, C.L., Lao, C.D., et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373:1 (2015), 23–34, 10.1056/nejmoa1504030.
42. Le, D.T., Lutz, E., Uram, J.N., Sugar, E.A., Onners, B., Solt, S., et al. Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. J. Immunother. 36:7 (2013), 382–389, 10.1097/cji.0b013e31829fb7a2.
43. Le, D.T., Uram, J.N., Wang, H., Bartlett, B.R., Kemberling, H., Eyring, A.D., et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372:26 (2015), 2509–2520, 10.1056/NEJMoa1500596.
44. Luke, J.J., Callahan, M.K., Postow, M.A., Romano, E., Ramaiya, N., Bluth, M., et al. Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience. Cancer 119:20 (2013), 3687–3695, 10.1002/cncr.28282.
45. Margolin, K., Ernstoff, M.S., Hamid, O., Lawrence, D., McDermott, D., Puzanov, I., et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol. 13:5 (2012), 459–465, 10.1016/s1470-2045(12)70090-6.
46. Massard, C., Gordon, M.S., Sharma, S., Rafii, S., Wainberg, Z.A., Luke, J., et al. Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. J. Clin. Oncol. 34:26 (2016), 3119–3125, 10.1200/jco.2016.67.9761.
47. McDermott, D.F., Drake, C.G., Sznol, M., Choueiri, T.K., Powderly, J.D., Smith, D.C., et al. Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab. J. Clin. Oncol. 33:18 (2015), 2013–2020, 10.1200/jco.2014.58.1041.
48. McDermott, D.F., Sosman, J.A., Sznol, M., Massard, C., Gordon, M.S., Hamid, O., et al. Atezolizumab, an anti-programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: long-term safety, clinical activity, and immune correlates from a phase ia study. J. Clin. Oncol. 34:8 (2016), 833–842, 10.1200/JCO.2015.63.7421.
49. Motzer, R.J., Escudier, B., McDermott, D.F., George, S., Hammers, H.J., Srinivas, S., et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med. 373:19 (2015), 1803–1813, 10.1056/NEJMoa1510665.
50. Nghiem, P.T., Bhatia, S., Lipson, E.J., Kudchadkar, R.R., Miller, N.J., Annamalai, L., et al. PD-1 blockade with pembrolizumab in advanced merkel-cell carcinoma. N. Engl. J. Med. 374:26 (2016), 2542–2552, 10.1056/nejmoa1603702.
51. O'Day, S.J., Maio, M., Chiarion-Sileni, V., Gajewski, T.F., Pehamberger, H., Bondarenko, I.N., et al. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann. Oncol. 21:8 (2010), 1712–1717, 10.1093/annonc/mdq013.
52. Pardoll, D.M., The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12:4 (2012), 252–264, 10.1038/nrc3239.
53. Postow, M.A., Luke, J.J., Bluth, M.J., Ramaiya, N., Panageas, K.S., Lawrence, D.P., et al. Ipilimumab for patients with advanced mucosal melanoma. Oncologist 18:6 (2013), 726–732, 10.1634/theoncologist.2012-0464.
54. Postow, M.A., Callahan, M.K., Wolchok, J.D., Immune checkpoint blockade in cancer therapy. J. Clin. Oncol. 33:17 (2015), 1974–1982, 10.1200/jco.2014.59.4358.
55. Postow, M.A., Chesney, J., Pavlick, A.C., Robert, C., Grossmann, K., McDermott, D., et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N. Engl. J. Med. 372:21 (2015), 2006–2017, 10.1056/nejmoa1414428.
56. Ralph, C., Elkord, E., Burt, D.J., O'Dwyer, J.F., Austin, E.B., Stern, P.L., et al. Modulation of lymphocyte regulation for cancer therapy: a phase II trial of tremelimumab in advanced gastric and esophageal adenocarcinoma. Clin. Cancer Res. 16:5 (2010), 1662–1672, 10.1158/1078-0432.ccr-09-2870.
57. Reck, M., Rodriguez-Abreu, D., Robinson, A.G., Hui, R., Csoszi, T., Fulop, A., et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N. Engl. J. Med. 375:19 (2016), 1823–1833, 10.1056/NEJMoa1606774.
58. Ribas, A., Chesney, J.A., Gordon, M.S., Abernethy, A.P., Logan, T.F., Lawson, D.H., et al. Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion. J. Transl. Med., 10, 2012, 236, 10.1186/1479-5876-10-236.
59. Ribas, A., Kefford, R., Marshall, M.A., Punt, C.J., Haanen, J.B., Marmol, M., et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J. Clin. Oncol. 31:5 (2013), 616–622, 10.1200/JCO.2012.44.6112.
60. Ribas, A., Puzanov, I., Dummer, R., Schadendorf, D., Hamid, O., Robert, C., et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 16:8 (2015), 908–918, 10.1016/S1470-2045(15)00083-2.
61. Ribas, A., Tumor immunotherapy directed at PD-1. N. Engl. J. Med. 366:26 (2012), 2517–2519, 10.1056/nejme1205943.
62. Rizvi, N.A., Mazieres, J., Planchard, D., Stinchcombe, T.E., Dy, G.K., Antonia, S.J., et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol. 16:3 (2015), 257–265, 10.1016/S1470-2045(15)70054-9.
63. Robert, C., Schadendorf, D., Messina, M., Hodi, F.S., O'Day, S., Efficacy and safety of retreatment with ipilimumab in patients with pretreated advanced melanoma who progressed after initially achieving disease control. Clin. Cancer Res. 19:8 (2013), 2232–2239, 10.1158/1078-0432.ccr-12-3080.
64. Robert, C., Ribas, A., Wolchok, J.D., Hodi, F.S., Hamid, O., Kefford, R., et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 384:9948 (2014), 1109–1117, 10.1016/s0140-6736(14)60958-2.
65. Robert, C., Schachter, J., Long, G.V., Arance, A., Grob, J.J., Mortier, L., et al. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. 372:26 (2015), 2521–2532, 10.1056/nejmoa1503093.
66. Robert, C., Long, G.V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., et al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 372:4 (2015), 320–330, 10.1056/nejmoa1412082.
67. Rosenberg, J.E., Hoffman-Censits, J., Powles, T., van der Heijden, M.S., Balar, A.V., Necchi, A., et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387:10031 (2016), 1909–1920, 10.1016/s0140-6736(16)00561-4.
68. Royal, R.E., Levy, C., Turner, K., Mathur, A., Hughes, M., Kammula, U.S., et al. Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J. Immunother. 33:8 (2010), 828–833, 10.1097/cji.0b013e3181eec14c.
69. Sangro, B., Gomez-Martin, C., de la Mata, M., Inarrairaegui, M., Garralda, E., Barrera, P., et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J. Hepatol. 59:1 (2013), 81–88, 10.1016/j.jhep.2013.02.022.
70. Seiwert, T.Y., Burtness, B., Mehra, R., Weiss, J., Berger, R., Eder, J.P., et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol. 17:7 (2016), 956–965, 10.1016/s1470-2045(16)30066-3.
71. Slovin, S.F., Higano, C.S., Hamid, O., Tejwani, S., Harzstark, A., Alumkal, J.J., et al. Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. Ann. Oncol. 24:7 (2013), 1813–1821, 10.1093/annonc/mdt107.
72. Small, E.J., Tchekmedyian, N.S., Rini, B.I., Fong, L., Lowy, I., A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin. Cancer Res. 13:6 (2007), 1810–1815, 10.1158/1078-0432.ccr-06-2318.
73. Spellman, A., Tang, S.C., Immunotherapy for breast cancer: past, present, and future. Cancer Metastasis Rev., 2016, 10.1007/s10555-016-9654-9.
74. Weber, J.S., O'Day, S., Urba, W., Powderly, J., Nichol, G., Yellin, M., et al. Phase I/II study of ipilimumab for patients with metastatic melanoma. J. Clin. Oncol. 26:36 (2008), 5950–5956, 10.1200/jco.2008.16.1927.
75. Weber, J., Thompson, J.A., Hamid, O., Minor, D., Amin, A., Ron, I., et al. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin. Cancer Res. 15:17 (2009), 5591–5598, 10.1158/1078-0432.ccr-09-1024.
76. Weber, J.S., Dummer, R., de Pril, V., Lebbe, C., Hodi, F.S., Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma. Cancer 119:9 (2013), 1675–1682, 10.1002/cncr.27969.
77. Weber, J.S., Kudchadkar, R.R., Yu, B., Gallenstein, D., Horak, C.E., Inzunza, H.D., et al. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. J. Clin. Oncol. 31:34 (2013), 4311–4318, 10.1200/jco.2013.51.4802.
78. Weber, J.S., D'Angelo, S.P., Minor, D., Hodi, F.S., Gutzmer, R., Neyns, B., et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 16:4 (2015), 375–384, 10.1016/s1470-2045(15)70076-8.
79. Wolchok, J.D., Saenger, Y., The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation. Oncologist 13:Suppl. 4 (2008), 2–9, 10.1634/theoncologist.13-s4-2.
80. Wolchok, J.D., Neyns, B., Linette, G., Negrier, S., Lutzky, J., Thomas, L., et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 11:2 (2010), 155–164, 10.1016/s1470-2045(09)70334-1.
81. Yang, J.C., Hughes, M., Kammula, U., Royal, R., Sherry, R.M., Topalian, S.L., et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J. Immunother. 30:8 (2007), 825–830, 10.1097/cji.0b013e318156e47e.